Table 4. Minimum detectable increases in relative risk of renal composite clinical outcomes in time-to-event analyses

PeriodOutcomeaNumber of OutcomesMinimum detectable effect sizes
80% Power90% Power
Risk Factor with 50% PrevalenceRisk Factor with 20% Prevalence1 SD Δ in quantitative variableRisk Factor with 50% PrevalenceRisk Factor with 20% Prevalence1 SD Δ in quantitative variable
a See Table 2 for definitions of outcomes. ESRD: End-stage renal disease; GFR Evt: event defined by a reduction in GFR; Scr Evt: event defined by a doubling of serum creatinine.
Period 1 AASK trial onlyESRD, GFR Evt, or death34035%46%16%42%55%19%
ESRD, GFR Evt26341%54%19%49%64%22%
ESRD or death24943%56%19%51%67%22%
Period 2 AASK trial + cohortESRD, Scr Evt, or death53028%36%13%33%42%15%
ESRD, Scr Evt41332%41%15%38%49%17%
ESRD or death45230%39%14%36%46%16%
Period 3 AASK cohort onlyESRD, Scr Evt, or death21047%62%21%56%75%25%
ESRD, Scr Evt17353%70%24%64%85%28%
ESRD or death17653%69%23%63%84%28%